Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Challenges to developing the quality of complex cancer surgery in LMICs

Choosing Wisely 2022 Mumbai

17 - 18 Sep 2022

Published: 19 Sep 2022

Views: 4673

Rating:

Save

Dr Shailesh V. Shrikhande - Tata Memorial Hospital, Mumbai, India

Dr Shrikhande speaks to ecancer about the challenges to developing the quality of complex cancer surgery in LMICs.

He talks about maintaining the quality of life of cancer patients when treating them and how this can be a challenge.

He also talks about the current situation of palliative care in India.

Related Videos

OncoAlert Round Up for September 15-21, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for September 15-21, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Time toxicity: the burden on cancer patients

Dr Arjun Gupta - University of Minnesota, Minneapolis, USA

Time toxicity: the burden on cancer patients ( Dr Arjun Gupta - University of Minnesota, Minneapolis, USA )

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast...

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German )

TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small...

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany

TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany )

The use of IORT at Universitätsmedizin Mannheim hospital

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany

The use of IORT at Universitätsmedizin Mannheim hospital ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany )

Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity...

Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )

Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in...

Dr Jason Luke - University of Pittsburgh, Pittsburgh, USA

Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours ( Dr Jason Luke - University of Pittsburgh, Pittsburgh, USA )

VT3989 is safe and well tolerated in patients with advanced malignant...

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA

VT3989 is safe and well tolerated in patients with advanced malignant mesothelioma and NF2m cancers ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant...

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )

More from ecancer